Results 41 to 50 of about 67,119 (304)

Clinical findings and immunophenotypic profile of plasma cell leukemia: a retrospective study in a comprehensive cancer center in Turkey

Medicine Science, 2021
Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs).
Nurgul Ozcan, Semih Basci, Eda Ozcan, Mehmet Bakirtas, Mehmet Sinan Dal, Merih Kizil Cakar, Fatma Meric Yilmaz, Fevzi Altuntas   +7 more
doaj   +1 more source

One Single Nucleotide Polymorphism of the TRPM2 Channel Gene Identified as a Risk Factor in Bipolar Disorder Associates with Autism Spectrum Disorder in a Japanese Population

Diseases, 2020
The transient receptor potential melastatin 2 (TRPM2) is a non-specific cation channel, resulting in Ca2+ influx at warm temperatures from 34 °C to 47 °C, thus including the body temperature range in mammals.
Naila Al Mahmuda, Shigeru Yokoyama, Toshio Munesue, Kenshi Hayashi, Kunimasa Yagi, Chiharu Tsuji, Haruhiro Higashida   +6 more
doaj   +1 more source

Cluster of Differentiation 38 Protein Significantly Adds to the Prognostic Value of Cytogenetic Risk in Patients with Acute Myeloid Leukemia

Oman Medical Journal, 2023
Objectives: There is some controversy regarding the clinical significance of cluster of differentiation 38 (CD38) protein in acute myeloid leukemia (AML).
Waiel M. A. AlKahiry, Hadeel S. T. Abdelsalam, Abdulrahman Mohammed Alhadi   +2 more
doaj   +1 more source

The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy

Cells, 2020
The CD38 antigen is expressed in several hematological malignancies, and the anti-CD38 monoclonal antibodies Daratumumab and Isatuximab have an established role in the therapy of multiple myeloma.
Eleonora Calabretta, Carmelo Carlo-Stella   +1 more
doaj   +1 more source

CD38 as a Therapeutic Target [PDF]

Molecular Medicine, 2006
The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations. As such, this molecule is a promising target for antibody therapy.
openaire   +2 more sources

The effect of sodium deoxyribonucleate with iron complex on the expression of surface markers of MT-4 cells infected with human immunodeficiency virus type 1 (HIV-1) (Retroviridae: Primate lentivirus group)

Вопросы вирусологии
Introduction. The persistence of immune dysfunction during therapy has serious consequences for the health of HIV-infected people. Therefore, an important direction is the search for drugs that can reduce the inflammatory potential of the immune system ...
Dmitry N. Nosik, Lyudmila B. Kalnina, Lyudmila M. Selimova, Ellie N. Kaplina   +3 more
doaj   +1 more source

Clinical Staging and Flowcytometric CD38 and Zap-70 Prognostic Indicators in Sudanese Patients with Chronic Lymphocytic Leukemia

Sudan Journal of Medical Sciences, 2020
Background: The clinical course of chronic lymphocytic leukemia is highly variable. The determination of ZAP70 and CD38 is increasingly utilized as prognostic factor for chronic lymphocytic leukemia.
Enaam Abdelrhman Abdelgader, Nada Hassan Eltayeb, Tasniem Ahmed Eltahir, Osama Ali Altayeb, Eman Abbass Fadul, Soaad Fadlallah Ali, Eldirdiri M. Abdelrhman   +6 more
doaj   +1 more source

THE FEATURES OF CONNEXINS EXPRESSION IN THE CELLS OF NEUROVASCLAR UNIT IN NORMAL CONDITIONS AND HYPOXIA IN VITRO

Бюллетень сибирской медицины, 2014
The aim of this research was to assess a role of connexin 43 (Cx43) and associated molecule CD38 in the regulation of cell-cell interactions in the neurovascular unit (NVU) in vitro in physiological conditions and in hypoxia.Materials and methods.
A. V. Morgun, N. V. Kuvacheva, Ye. D. Khilazheva, T. Ye. Taranushenko, A. B. Salmina   +4 more
doaj   +1 more source

Enhanced tumor regression and synergistic activity of anti-CD38-IFNα(att) compared to standard MM therapeutics.

, 2016
(A) Tumor volumes from NCI-H929 tumor bearing SCID mice treated with 5mg/kg anti-CD38-IFNα(att), twice a week for 3 weeks or standard MM therapeutic agents including dexamethasone (10 mg/kg, daily for 28 days), lenalidomide (25 mg/kg, daily for 21 days),
James Berenson (3111285), Anthony Doyle (577129), Yong Yun (3111264), Haiming Chen (355433), David S. Wilson (36463), Maya Sokolovsky (3111255), Moti Rosenstock (3111276), Eric Sanchez (3111288), Tetsuya Taura (3111270), Steffen Nock (3111279), Collette Behrens (3111261), Angela Sho (3111273), Sarah L. Pogue (3111267), Hussein Hallak (3019602), Mingying Bi (3111258), Glen Mikesell (3111282)   +15 more
core   +1 more source

Antigen specificity index (ASI) of anti-CD38-IFNα and attenuated variants.

, 2016
Antigen specificity index (ASI) of anti-CD38-IFNα and attenuated variants.
James Berenson (3111285), Anthony Doyle (577129), Yong Yun (3111264), Haiming Chen (355433), David S. Wilson (36463), Maya Sokolovsky (3111255), Moti Rosenstock (3111276), Eric Sanchez (3111288), Tetsuya Taura (3111270), Steffen Nock (3111279), Collette Behrens (3111261), Angela Sho (3111273), Sarah L. Pogue (3111267), Hussein Hallak (3019602), Mingying Bi (3111258), Glen Mikesell (3111282)   +15 more
core   +1 more source